论文部分内容阅读
苏格兰的研究人员通过随机、双盲和安慰剂的对照研究,说明每天服用一次氨酰心安(Atenolol),看来可降低血压,减少继发蛋白尿的发生率。氨酰心安对于减少呼吸窘迫综合症的发生率较传统产科方法处理轻度至中等度妊娠伴发高血压(PAH)更有效,因此也降低了住院率。应用这种β-阻滞剂不至于增加胎儿或新生儿的副作用。根据安慰剂组的39名PAH妇女经卧床和镇静剂治疗的资料,和每天给予100mg氨酰心安的46名妇女的治疗资料,只有服药组的血压下降。此外,参加研究时无蛋白尿的妇女中,在服用安慰剂期间有10名妇女以后发生蛋白尿;服用氨酰心安组的妇女只有3名发生蛋白尿。已经出现蛋白尿者,β-阻滞剂不能消除,这提示降压能影响产生蛋白尿的过程,但血压降低不能逆转肾病变。在可能发生副作用的组中,未见到有明显的差别。从婴儿的生长迟缓、低血糖、呼吸窘迫综合征和血胆红素过高来看,两组婴儿的发生率差不多,氨酰心安组的婴儿虽比较常见心搏徐缓,但不需要增加心率。两组婴儿收缩压相
In a randomized, double-blind, placebo-controlled study, researchers in Scotland showed that taking Atenolol daily can appear to lower blood pressure and reduce the incidence of secondary proteinuria. Atenolol is more effective in reducing the incidence of respiratory distress syndrome than the traditional obstetric approach to mild to moderate pregnancy-associated hypertension (PAH) and therefore also reduces hospitalization rates. The use of such beta-blockers does not increase fetal or neonatal side effects. Based on data from 39 PAH women in the placebo group treated with ambulatory and sedatives and 46 women given 100 mg atenzan per day, only the medication group experienced a decrease in blood pressure. In addition, proteinuria occurred in 10 women who took proteinuria during the study, compared with 10 during placebo, and only 3 in women who received atenolol. Already proteinuria, β-blockers can not be eliminated, suggesting that hypotension can affect the process of proteinuria, but blood pressure can not reverse the renal disease. No significant differences were seen in the group of possible side effects. From the baby’s growth retardation, hypoglycemia, respiratory distress syndrome and hyperbilirubinemia point of view, the incidence of infants in both groups is similar, although infants with atenolol more common bradycardia, but do not need to increase heart rate. Two groups of infants systolic pressure